# Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer

> **NCT01498458** · PHASE1 · COMPLETED · sponsor: **GBG Forschungs GmbH** · enrollment: 9 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Pazopanib plus capecitabine

## Key facts

- **NCT ID:** NCT01498458
- **Lead sponsor:** GBG Forschungs GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-12
- **Final completion:** 2014-05
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2022-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01498458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01498458, "Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01498458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*